SEATTLE --(BUSINESS WIRE)--Nov. 26, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced participation in an analyst-led fireside chat at